Wells Fargo initiated coverage on Relay Therapeutics with a new price target
$RLAY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00